POSSIBILITIES OF USING NOLODATAK (FLUPIRTINE) IN THE TREATMENT OF MUSCULOSKELETAL PAIN SYNDROMES

DOI: https://doi.org/10.29296/25877305-2018-04-08
Download full text PDF
Issue: 
4
Year: 
2018

O. Badalyan, S. Burd, A. Lebedeva N.I. Pirogov Russian National Research Medical University, Moscow

There is a high prevalence of musculoskeletal pain syndromes that are associated with long-term disability, worse quality of life in patients, and considerable material costs of treatment and rehabilitation; in addition, undesirable side effects can occur during pharmacotherapy. The paper considers whether Nolodatak (flupirtine) that has an analgesic, muscle relaxant, and neuroprotective effect may be used.
Keywords: 
musculoskeletal pain syndromes
flupirtine
Nolodatak

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Voznesenskaja T.G. V kn.: Bolevye sindromy v nevrologicheskoj praktike. Pod red. A.M. Vejna / M.: MEDpress, 1999; 217–84.
  2. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nyh so spondilogennoj dorsopatiej // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2006; 106 (11): 46–9.
  3. Nasonov E.L., Nasonova V.A. Revmatologija / M.: GEOTAR-Media, 2005.
  4. Nasonov E.L., Lazebnik L.B., Kukushkin M.L. i dr. Primenenie nesteroidnyh protivovospalitel'nyh preparatov / M.: IMA-press, 2009.
  5. Karateev A.E., Nasonova V.A. Razvitie i retsidivirovanie jazv zheludka i dvenadtsatiperstnoj kishki u bol'nyh, prinimajuschih nesteroidnye protivovospalitel'nye preparaty: vlijanie standartnyh faktorov riska // Ter. arh. – 2008; 80 (5): 62–6.
  6. Barantsevich E., Andreev V. Vozmozhnosti lechenija hronicheskoj boli pri pojasnichno-kresttsovoj radikulopatii // Vrach. – 2012; 11: 13–9.
  7. Nasonov E.L., Jahno N.N., Karateev A.E. i dr. Obschie printsipy lechenija skeletno-myshechnoj boli. Mezhdistsiplinarnyj konsensus // Nauchno-prakt. revmatol. – 2016; 54 (3): 247–65.
  8. Esin R.G., Lotfullina N.Z., Esin O.R. Tservikalgija, dorzalgija, ljumbalgija. Differentsial'naja diagnostika, differentsirovannaja terapija / Kazan': IITs UD Prezidenta RT, 2015.
  9. Banerjee M., Bhattacharyya K. et al. Comparative study of efficacy and tolerability of flupirtine v.s. tramadol in non-steroidal anti-inflammatory drug intolerant mechanical low back pain // Ind. J. Rheumatol. – 2012; 7 (3): 135–40.
  10. Ueberall A., Eberhardt A., Mueller-Schwefe H. Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice // Int. J. Gen Med. – 2016; 9: 39–51.
  11. Qaseem A., Wilt T., McLean R. et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians // Ann. Intern. Med. – 2017; 166 (7): 514–30. DOI: 10.7326/M16-2367.
  12. Brown D., Passmore G. Neural KCNQ (Kv7) channels // Br. J. Pharmacol. – 2009; 156 (8): 1185–95.
  13. Rivera-Arconada I., Vicente-Baz J., Lopez-Garcia J. Targeting Kv7 channels in pain pathways // Oncotarget. – 2017; 8: 1254–5. DOI: 10.18632/oncotarget.15261.
  14. Szelenyi I. Flupirtine, a rediscovered drug, revisited // Inflamm. Res. – 2013; 62 (3): 251–8.
  15. Fleckenstein J., Sittl R., Averbeck B. et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo – therapeutic potential for peripheral neuropathi-es: results of a randomised controlled trial // J. Transl. Med. – 2013; 11: 34–9.
  16. Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antago-nism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. – 1999; 106 (9–10): 857–67.
  17. Klinger F., Bajric M., Salzer I. et al. d-Subunit-containing GABAA receptors are preferred tar-gets for the centrally acting analgesic flupirtine // Br. J. Pharmacol. – 2015; 172 (20): 4946–58.
  18. Klinger F., Geier P., Dorostkar M. et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine // Br. J. Pharmacol. – 2012; 166: 1631–42.
  19. Harish S., Bhuvana K., Bengalorkar M. et al. Flupirtine: Clinical pharmacology // J. Anaesthesiol. Clin. Pharmacol. – 2012; 28 (2): 172–7.
  20. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Expert Opin. Pharmacother. – 2009; 10 (9): 1495–500.
  21. Bientinesi R., Mancuso C., Martire M. et al. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression // Naunyn Schmiedebergs Arch. Pharmacol. – 2017; 390 (2): 127–37.
  22. Takagi H., Hashitani H. Effects of K+-channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder // Eur. J. Pharmacol. – 2016; 789: 179–86.
  23. Ahuja V., Mitra S., Kazal S. et al. Comparison of analgesic efficacy of flupirtine maleate and ibuprofen in gynaecological ambulatory surgeries: A randomized controlled trial // Indian J. Anaesth. – 2015; 59 (7): 411–5.
  24. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tense-ness. Results of a postmarket surveillance study // Fortschr. Med. Orig. – 2003; 121 (1): 11–8.
  25. Sampath D., Valdez R., White A. et al. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy // Neuropharmacology. – 2017; 123: 126–35 DOI: 10.1016/j.neuropharm.2017.06.002.
  26. Sattler M., Williams S., Neusch C. et al. Flupirtine as Neuroprotective Add-On Therapy in Autoimmune Optic Neuritis // Am. J. Pathol. – 2008; 173 (5): 1496–507